The inspection of medicaments is now aligned between Switzerland and the United States, with the aim of saving on paperwork and cost for the pharmaceutical industry.
This content was published on
1 minute
swissinfo.ch/mga
The Mutual Recognition Agreement (MRA) for inspection of medicinal products came into force on Thursday. The deal allows authorities from both countries to share documents from their routine inspections of pharmaceutical manufacturing facilities, thus erasing duplication of efforts in each country.
This agreement comes as the complexities of foreign production and sourcing in supply chains for medicine increase, making them more difficult and costly to monitor.
The respective inspection authorities, Swissmedic and the Food and Drug Administration, are working towards extending the inspection alignment to vaccines.
After the European Union, the US is the second-most important trading partner for research-based pharmaceutical companies in Switzerland. In 2021, the US accounted for 26% of Swiss pharma exports (CHF109 billion) and 10% of imports.
A similar medicaments MRA between the EU and Switzerland on pharmaceutical products is expected to expire in a few years. But the current political impasse between the two parties.
If the arrangement isn’t renewed, Swiss companies would need to conduct multiple checks and inspections, which could cost the sector an estimated CHF500 million ($558 million) a year in extra costs.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
This content was published on
Consumer prices picked up again in June in Switzerland, after briefly dipping into negative territory the previous month.
Switzerland and US sign deal on pharmaceutical supply chain
This content was published on
US and Swiss authorities have agreed to share inspection documents on pharmaceutical manufacturing facilities in a move to improve efficiency and safety.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.